XML 17 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Balance Sheets (USD $)
Mar. 31, 2012
Dec. 31, 2011
Assets    
Cash and cash equivalents $ 20,923,750 $ 9,748,491
Other current assets 79,030 87,176
Total current assets 21,002,780 9,835,667
In-process research and development 5,441,839 5,441,839
Goodwill 629,752 629,752
Total assets 27,074,371 15,907,258
Liabilities and equity    
Notes payable, current portion 677,778 877,778
Accounts payable and accrued expenses 467,524 666,640
Interest payable, current portion 76,793 61,941
Total current liabilities 1,222,095 1,606,359
Notes payable, noncurrent portion, at fair value 4,664,697 4,664,697
Total liabilities 5,886,792 6,271,056
Commitments and contingencies      
Equity:    
Preferred stock, $0.001 par value per share (10,000,000 shares authorized, 1,108,816 and 413,388 issued and outstanding as of March 31, 2012 and December 31, 2011, respectively, aggregate liquidation value of $22,176,320 and $8,267,760 at March 31, 2012 and December 31, 2011, respectively) 1,109 413
Common stock, $0.001 par value per share (500,000,000 shares authorized, 5,061,399 shares issued and outstanding at March 31, 2012 and December 31, 2011) 5,061 5,061
Contingently issuable shares 6 6
Additional paid-in capital 22,841,334 10,472,115
Deficit accumulated in development stage (11,109,164) (853,074)
Total TG Therapeutics, Inc. and subsidiaries equity 11,738,346 9,624,521
Non-controlling interest in subsidiary 9,449,233 11,681
Total equity 21,187,579 9,636,202
Total liabilities and equity $ 27,074,371 $ 15,907,258